According to a press release, German pharma company Boehringer Ingelheim has acquired Saiba Animal Health AG, located in Pfäffikon in the Swiss canton of Schwyz. Saiba was established in 2013 as a spin-off of the University of Zurich and has developed a broad, innovative pipeline of therapeutic vaccinations based on virus-like particles. The Saiba Animal Health innovative technology platform is based on a novel therapeutic vaccination approach that creates an immune response and targets chronic diseases such as allergy, inflammation and pain.
“Our pets live longer which creates different needs for their medical care, and often without good existing treatment options”, says Eric Haaksma, Head of Global Innovation, Animal Health at Boehringer Ingelheim. He adds that Boehringer is “very excited about the potential of Saiba Animal Health’s groundbreaking technology platform, which could result in a more specific and longer-lasting therapeutic response to chronic diseases in companion animals than current approaches.”
Pointing to the longstanding partnership with Boehringer Ingelheim, Gary T. Jennings, CEO of Saiba Animal Health, says that the two companies joining forces “will pave the way for a whole new class of therapeutic medicines for pets, with a true impact on the lives of animals and their owners.” ce/gba
Related news
Meet with an expansion expert
Our services are free of charge and include:
- Introduction to key contacts in industry, academia, and government
- Advice on regulatory framework, taxes, labor, market, and setting up a company
- Custom-made fact-finding visits, including office and co-working space